Gilead Sciences

At Gilead, our focus is on turning scientific innovation into real-world impact. We’re committed to delivering our medicines to people who need them most, and our recent agreement with The Global Fund will help expand access to our #HIV prevention medicine once approved in high-incidence, resource-limited countries. #IAS2025

Yvette Raphael played a pivotal role in Gilead’s #HIV prevention trials, ensuring that the voices of young women and adolescent girls were not only heard, but prioritized. Alongside Moupali Das and others, she worked to build a blueprint to help inform the future of HIV innovation. Inclusion in clinical trials is essential — not just for advancing science, but for ensuring that HIV treatment and prevention strategies help meet the needs of all communities. When women are represented in research, outcomes improve for everyone. #IAS2025 

#InTheNews: Researchers at Penn Medicine, University of Pennsylvania Health System are exploring how CAR T-cell therapy might one day help patients with aggressive brain cancers like #glioblastoma. While this treatment is still under investigation for brain tumors, the research offers hope for future advances in treatment. We’re proud to collaborate with Penn Medicine to help discover the next generation of emerging therapeutic options for patients. http://bit.ly/4kx81sA #GBMDay

We’re announcing interim results from our new global survey, which once complete, will be one of the largest global surveys of people living with #HIV. Co-created with community representatives from around the world, this survey includes 2,532 participants across 11 countries and amplifies the experiences of people living with HIV – many from underrepresented groups.   The key findings highlight priorities for the broad range of people and communities affected by HIV:  🌍 The need for earlier initiation of antiretroviral therapy   🌍 The importance of person-centered care and treatment choices   🌍 The ongoing work required to reduce HIV-related stigma  At Gilead, we’re committed to putting people at the center of HIV care. Learn more: http://gilead.inc/3TC9DpY #IAS2025 

Scientific progress is measured in more than data points. It’s measured in the people reached, the questions answered and the impact made. From diverse clinical trials to advances in virology, oncology and inflammation, these numbers reflect the real-world progress behind our work. Because at Gilead, we innovate for impact. Read more in our 2024 Responsible Business and Impact Report: https://gilead.inc/3Eu4JHC

Helping end the HIV epidemic means listening to the real experiences and needs of people living with HIV as well as those who need PrEP (pre-exposure prophylaxis). That's why we’re focused on developing innovative solutions, expanding access to care and working closely with communities to help ensure that no one is left behind. Every step we take is guided by the goal of making a tangible difference for those affected by #HIV. At #IAS2025, we’re proud to join global industry leaders to share our progress and reinforce our commitment to accessible, transformative care that helps people get the support they need.  

#GileadNews: We’re presenting new data at #IAS2025 on the safety and efficacy of our #HIV prevention medication across underrepresented populations, including pregnant and lactating women and young people. This person-centered, inclusive research is part of our ambition to help meet people where they are. Read more: https://gilead.inc/4kzk5cV

#GileadNews: Today, the World Health Organization (WHO) issued new guidelines for the use of our long-acting #HIV prevention medication, as well as new HIV testing protocols for long-acting prevention medications. These new guidelines help to align global stakeholders and inform decision making as we strive to help transform the HIV prevention landscape. Read more: https://gilead.inc/40MiDMX

Earlier this month, I was honored to receive the inaugural Corporate Leadership Award on behalf of Gilead Sciences from the Global Black Economic Forum at the Essence Festival. It was a deeply meaningful honor—one that belongs to every colleague at Gilead working to advance equitable healthcare worldwide. The festival was a powerful reminder of what’s possible in health equity when community and culture come together. It was a privilege to introduce a fascinating panel moderated by Trina Scott and panelists Tamar Braxton, Raheem DeVaughn and Contessa Metcalfe, MD, MSPH, who focused on reframing Black women’s health, HIV prevention and breast cancer awareness. The conversations we shared with advocates, artists and health leaders throughout the festival underscored the urgency and the promise of this work. Our partnership with #GBEF continues to inspire us to break down barriers, amplify trusted voices and ensure transformative medicines reach people who need or want them. Together, we are not just envisioning the future, we are building it. #HealthEquity #LeadershipInAction

At Gilead, we’re committed to meeting the needs of people most affected by #HIV. Next week, we’ll be at #IAS2025, highlighting the intentional inclusion of women – including and especially pregnant and lactating women, and adolescent girls and young women – in our HIV prevention trial program. Learn more about our work in this area and about our recently launched UK Women & HIV campaign here: https://gilead.inc/40AL4h9